Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fotemustine and interferon alpha2b in metastatic malignant melanoma.
Weichenthal M, Mohr P, Stephan U, Altenhoff J, Kowalzick L, Marseille A, Sarkany M, Hossfeld DK, Breitbart EW. Weichenthal M, et al. Among authors: mohr p. J Cancer Res Clin Oncol. 1998 Jan;124(1):55-9. doi: 10.1007/s004320050134. J Cancer Res Clin Oncol. 1998. PMID: 9498836 Clinical Trial.
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Among authors: mohr p. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial.
Adjuvant therapy in melanoma.
Mohr P, Weichenthal M, Hauschild A. Mohr P, et al. Onkologie. 2003 Jun;26(3):227-33. doi: 10.1159/000071617. Onkologie. 2003. PMID: 12845206 Review.
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Avril MF, et al. Among authors: mohr p. J Clin Oncol. 2004 Mar 15;22(6):1118-25. doi: 10.1200/JCO.2004.04.165. J Clin Oncol. 2004. PMID: 15020614 Clinical Trial.
Low-frequency ultrasound treatment of chronic venous ulcers.
Weichenthal M, Mohr P, Stegmann W, Breitbart EW. Weichenthal M, et al. Among authors: mohr p. Wound Repair Regen. 1997 Jan-Mar;5(1):18-22. doi: 10.1046/j.1524-475X.1997.50107.x. Wound Repair Regen. 1997. PMID: 16984453
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C, Wagner SN, Schadendorf D, Ellwanger U, Garbe C; German Dermatologic Cooperative Oncology Group. Eigentler TK, et al. Melanoma Res. 2008 Oct;18(5):353-8. doi: 10.1097/CMR.0b013e32830e3936. Melanoma Res. 2008. PMID: 18781134 Clinical Trial.
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingstone E, Garbe C. Hauschild A, et al. Among authors: mohr p. J Clin Oncol. 2009 Jul 20;27(21):3496-502. doi: 10.1200/JCO.2008.21.3892. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433681 Clinical Trial.
589 results